Agennix

Website Links

Description

Agennix is a privately held biotechnology company whose lead molecule, Talactoferrin Alfa (talactoferrin; TLF), is an immunomodulatory protein. Agennix is currently preparing to initiate Phase III development of oral talactoferrin for cancer, and topical talactoferrin gel for wound healing. Liquid talactoferrin is an oral anti-cancer drug that has shown activity both as monotherapy and in combination with other chemotherapeutic agents. In Non-Small Cell Lung Cancer (NSCLC), talactoferrin was evaluated in a Phase II, double-blind, placebo-controlled clinical trial where patients received standard first-line chemotherapy combined with either oral talactoferrin or placebo.

Products & services

Similar companies nearby